Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Novartis receives European licence for Aimovig® (erenumab), the first treatment designed specifically for the prevention of migraine

Human pain nerves grown in the lab that can release CGRP and be used to identify new migraine treatments

Novartis today announced that the European Medicines Agency has granted a licence for the use of Aimovig® (erenumab) for the prevention of migraine in adults who experience at least four migraine days per month. 

Erenumab is the first and only licensed preventative treatment designed specifically for migraine that blocks the calcitonin gene-related peptide (CGRP) receptor, thought to be involved in the transmission of the pain signals associated with migraine. Zam Cader, who leads the Translational Molecular Neuroscience Group in our Department, is undertaking underpinning research on how CGRP may be important in migraine. He has also been involved in running clinical trials on CGRP antibody therapies at the Oxford Headache Centre.

Erenumab has been shown to reduce the average number of monthly migraine days in both episodic and chronic migraine patients, including those who have tried existing treatment options. Today’s news represents a new approach for the clinical community in our ability to treat those that suffer most with migraine.
- Zameel Cader, NDCN

Migraine is a complex and debilitating neurological condition that affects each individual differently. Latest information shows that over 610,000 people in the UK are estimated to experience chronic migraine (15 or more headache days per month of which eight involve migraine symptoms). Research shows that around £9.7 billion a year is lost in the UK alone due to migraine through direct (treating patients) and indirect (lost productivity) costs, yet migraine remains the least publicly funded of all neurological illnesses relative to its economic impact.

Novartis is working closely with all stakeholders to ensure eligible patients can start benefitting from this treatment as quickly as possible. A bespoke patient support programme and range of resources are also being developed in order to provide as much support as possible to patients and healthcare professionals.

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.

Insights into the molecular pathways of progressive multiple sclerosis

Text by Ian Fyfe for 'Nature Reviews Neurology'

Discovery of gene involved in chronic pain creates new treatment target

Our researchers have discovered a gene that regulates pain sensitisation by amplifying pain signals within the spinal cord. This is helping them to understand an important mechanism underlying chronic pain in humans, and provides a new treatment target.